Saturday, September 10, 2011

The Rise of the Chinese Mega Pharmaceutical Company

If there was any doubt that the growth of the pharmaceutical industry is moving to Asia, there is nothing more concrete than the following showing Harbin Pharmaceuticals new Headquarters building shown in this link:

http://ibankcoin.com/news/2011/09/10/shock-photos-china-rubs-transfer-of-wealth-in-americas-face/

While controversial in its opulence, there is no mistaking the increase in both demand and meeting this demand with home grown Chinese businesses, for example, here is some interesting information from Harbin's website which amply demonstrates that this is a serious competitor on the horizon both in the region and potentially globally:

Harbin Pharmaceutical Group Co., Ltd. is a state-owned joint venture after restructuring through capital and stock increases in 2005. It sets up two public companies listed on Shanghai Stock Exchange (i.e., Harbin Pharmaceutical Group Holding Co., Ltd. and Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.), and 27 wholly-owned, holding and joint-stock companies. The registered capital totals 3.7 billion yuan, the total assets amounts to 14.65 billion yuan, and the ownership interests reach 8.96 billion yuan. Staffed with total 18, 382 employees, the Group has 12 affiliated pharmaceutical companies. 
  Harbin Pharmaceutical Group Co., Ltd. integrates pharmaceutical manufacturing, trade, and scientific research as a whole, covering the seven industrial fields of antibiotics, chemical pharmaceutical preparations, non-prescription drugs and health-care products, traditional Chinese medicines, bioengineering medicines, animal vaccines and veterinary drugs, and pharmaceutical circulation. Its products are of more than 1,000 varieties, over 20 kinds of dosage formulations, and 7 major series, involving antibiotic bulk drugs and powder for injection, Chinese patent drugs, Chinese medicine powder for injection, and comprehensive preparations. The Group has an annual output capacity of 13,000 tons of antibiotics and intermediates, 3 billion of western medicine powder for injection, 400 million of point injection, 20 billion of tablets, 12.5 billion of capsules, 3 billion of oral liquid, and 45 billion of animal vaccines. The affiliated manufacturers of the Group have all passed GMP certification, the main circulation enterprises, GSP certification, and General Pharmacy Factory, Sanjing Medicine Co., Ltd., and some other subordinated enterprises, the certifications of ISO9001, ISO14001 and OHSAS18001. Harbin Pharmaceutical Group Co., Ltd. has established more than 130 sales offices spreading over 30 major cities in the country and 200 retail chain pharmacies to form the marketing network with wide coverage and strong functions.

Source:  http://www.hayao.com/Corporation/hpgc.asp?cInfoId=194&dInfoId=259

More to come as we discuss the inferences for the industry